ECSP11011377A - Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona - Google Patents

Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona

Info

Publication number
ECSP11011377A
ECSP11011377A EC2011011377A ECSP11011377A ECSP11011377A EC SP11011377 A ECSP11011377 A EC SP11011377A EC 2011011377 A EC2011011377 A EC 2011011377A EC SP11011377 A ECSP11011377 A EC SP11011377A EC SP11011377 A ECSP11011377 A EC SP11011377A
Authority
EC
Ecuador
Prior art keywords
quinazolinadiona
derivatives
therapeutic applications
cardiovascular
domain
Prior art date
Application number
EC2011011377A
Other languages
English (en)
Inventor
Fabrice Viviani
Philip Janiak
Gilbert Marciniak
Jean-Francois Nave
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ECSP11011377A publication Critical patent/ECSP11011377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención tiene por objeto la utilización de compuestos de la fórmula (I) en estado de base, de hidrato, de solvato, o de sus mezclas como medicamentos o para la preparación de medicamentos destinados al tratamiento de al menos una enfermedad cardiovascular y/o a prevenir la aparición de al menos una enfermedad cardiovascular.
EC2011011377A 2009-04-09 2011-10-06 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona ECSP11011377A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0901755A FR2944206B1 (fr) 2009-04-09 2009-04-09 Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Publications (1)

Publication Number Publication Date
ECSP11011377A true ECSP11011377A (es) 2011-11-30

Family

ID=41181038

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011377A ECSP11011377A (es) 2009-04-09 2011-10-06 Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona

Country Status (34)

Country Link
US (1) US8846654B2 (es)
EP (1) EP2416777B1 (es)
JP (1) JP5685578B2 (es)
KR (1) KR101686267B1 (es)
CN (1) CN102458409B (es)
AR (1) AR076232A1 (es)
AU (1) AU2010233596B2 (es)
BR (1) BRPI1010256A2 (es)
CA (1) CA2758234A1 (es)
CL (1) CL2011002525A1 (es)
CO (1) CO6440577A2 (es)
CR (1) CR20110527A (es)
CY (1) CY1115987T1 (es)
DK (1) DK2416777T3 (es)
DO (1) DOP2011000306A (es)
EA (1) EA020984B1 (es)
EC (1) ECSP11011377A (es)
ES (1) ES2528633T3 (es)
FR (1) FR2944206B1 (es)
HR (1) HRP20150106T1 (es)
HU (1) HUE024161T2 (es)
IL (1) IL215610A (es)
MA (1) MA33254B1 (es)
MX (1) MX2011010645A (es)
NI (1) NI201100180A (es)
NZ (1) NZ595660A (es)
PL (1) PL2416777T3 (es)
PT (1) PT2416777E (es)
SG (2) SG10201400420PA (es)
SI (1) SI2416777T1 (es)
TN (1) TN2011000506A1 (es)
TW (1) TWI457330B (es)
UY (1) UY32555A (es)
WO (1) WO2010116090A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9499496B2 (en) 2012-06-05 2016-11-22 University Of Kansas Inhibitors of respiratory syncytial virus
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
US20240208923A1 (en) 2021-03-10 2024-06-27 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc6a19 function
AU2023326563A1 (en) 2022-08-18 2025-02-27 Mitodicure Gmbh Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance
WO2024259100A2 (en) * 2023-06-14 2024-12-19 Jnana Therapeutics Inc. Piperidine inhibitor of slc6a19 function
US12258345B1 (en) 2023-12-12 2025-03-25 King Faisal University Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879393A (en) * 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
JPS56164172A (en) * 1980-05-22 1981-12-17 Masayuki Ishikawa Novel 2,4 1h,3h -quinazolinedione derivative
DE3172006D1 (en) * 1980-05-22 1985-10-03 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
WO1999054284A1 (en) 1998-04-20 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
WO2001044228A2 (fr) 1999-12-14 2001-06-21 Sanofi-Synthelabo Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique
US20090111837A1 (en) 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US7846664B2 (en) 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
WO2008119057A2 (en) 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
TW200911755A (en) 2007-04-19 2009-03-16 Astellas Pharma Inc Bicyclic heterocyclic compounds
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione

Also Published As

Publication number Publication date
HRP20150106T1 (hr) 2015-05-08
AU2010233596A1 (en) 2011-11-03
SI2416777T1 (sl) 2015-02-27
DOP2011000306A (es) 2011-10-31
HK1165997A1 (en) 2012-10-19
TW201040155A (en) 2010-11-16
IL215610A0 (en) 2011-12-29
JP2012523398A (ja) 2012-10-04
KR20120005499A (ko) 2012-01-16
SG10201400420PA (en) 2014-05-29
TWI457330B (zh) 2014-10-21
KR101686267B1 (ko) 2016-12-13
SG175131A1 (en) 2011-11-28
EA201171229A1 (ru) 2012-12-28
PT2416777E (pt) 2015-02-04
IL215610A (en) 2013-07-31
UY32555A (es) 2010-11-30
CN102458409B (zh) 2014-06-18
CA2758234A1 (fr) 2010-10-14
NI201100180A (es) 2012-01-11
WO2010116090A1 (fr) 2010-10-14
AR076232A1 (es) 2011-05-26
BRPI1010256A2 (pt) 2016-03-22
MA33254B1 (fr) 2012-05-02
HUE024161T2 (hu) 2016-02-29
ES2528633T3 (es) 2015-02-11
CO6440577A2 (es) 2012-05-15
DK2416777T3 (en) 2015-02-09
NZ595660A (en) 2013-03-28
US20120184522A1 (en) 2012-07-19
PL2416777T3 (pl) 2015-05-29
EA020984B1 (ru) 2015-03-31
CN102458409A (zh) 2012-05-16
AU2010233596B2 (en) 2016-06-23
MX2011010645A (es) 2012-01-19
EP2416777A1 (fr) 2012-02-15
CY1115987T1 (el) 2017-01-25
US8846654B2 (en) 2014-09-30
FR2944206B1 (fr) 2012-12-28
EP2416777B1 (fr) 2014-11-12
TN2011000506A1 (fr) 2013-05-24
JP5685578B2 (ja) 2015-03-18
CL2011002525A1 (es) 2012-02-17
FR2944206A1 (fr) 2010-10-15
CR20110527A (es) 2014-05-12

Similar Documents

Publication Publication Date Title
DOP2010000089A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
CO6751268A2 (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
NI201100180A (es) Aplicaciones terapéuticas en el dominio cardiovascular de derivados de quinazolinadiona
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
CO6430429A2 (es) Aplicaciones terapéuticas de derivados de quinazolinodiona
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
PH12015500373A1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia